Pyrimidine-2,4,6-triones are a new class of voltage-gated L-type Ca2+ channel activators

  title={Pyrimidine-2,4,6-triones are a new class of voltage-gated L-type Ca2+ channel activators},
  author={Nadine J Ortner and Gabriella Bock and David H. F. Vandael and Robert Mauersberger and Henning Joerg Draheim and Ronald Gust and Emilio Carbone and Petronel Tuluc and J{\"o}rg Striessnig},
  booktitle={Nature communications},
Cav1.2 and Cav1.3 are the main L-type Ca(2+) channel subtypes in the brain. Cav1.3 channels have recently been implicated in the pathogenesis of Parkinson's disease. Therefore, Cav1.3-selective blockers are developed as promising neuroprotective drugs. We studied the pharmacological properties of a pyrimidine-2,4,6-trione derivative (1-(3-chlorophenethyl)-3-cyclopentylpyrimidine-2,4,6-(1H,3H,5H)-trione, Cp8) recently reported as the first highly selective Cav1.3 blocker. Here we show, in… CONTINUE READING
15 Citations
38 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 15 extracted citations


Publications referenced by this paper.
Showing 1-10 of 38 references

Structure-activity relationship of N,N’-disubstituted pyrimidinetriones as Cav1.3 calcium channel-selective antagonists for Parkinson’s disease

  • S Kang
  • J. Med. Chem
  • 2013

Structural determinants of Cav1.3 L-type calcium channel gating

  • A. Lieb, A. Scharinger, S. Sartori, M. J. Sinnegger-Brauns, J. Striessnig
  • Channels (Austin)
  • 2012

Functional properties of a newly identified C-terminal splice variant of Cav1.3 L-type Ca2þ channels

  • G Bock
  • J. Biol. Chem. 286,
  • 2011

Similar Papers

Loading similar papers…